STAT Plus: Biogen believes failed Alzheimer’s trials may still offer clues to way forward on treatment
RUBY WALLAU FOR STAT
Dr. Michael Ehlers, Biogen's head of research, said the company say "there are gradations of read-through" on the data from the aducanumab trials.
.png)
No hay comentarios:
Publicar un comentario